To product overview AustriaTo global product overview
Nalbuphin Amomed is intended for the short-term treatment of moderate to severe pain, e.g. after operations, in obstetrics and gynecology, in myocardial infarction, to relieve opioid-induced respiratory depression after anaesthesia, e.g. after fentanyl combination anesthesia and as part of a combination as part of a combination anaesthesia.
Active ingredient: nalbuphine | Dosage form: solution for injection | Strength: 10 mg/ml
Marketing authorisation holder: Amomed Pharma GmbH